Featuring

Paul Hudson
Chief Executive Officer

Jean-Baptiste de Chatillon
Chief Financial Officer

Bill Sibold
Specialty Care

Olivier Charmeil
General Medicines

John Reed
R&D

Thomas Triomphe
Vaccines

Julie van Ongevalle
Consumer Healthcare

Roy Papatheodorou
General Counsel

Highlights

"We’re off to a good start in 2022 thanks to a strong commitment to our strategy. We’re proud of the progress made in Immunology, with a broad pipeline of 13 potential new treatments in development."

Paul Hudson, CEO at Sanofi

Webinar

14:30 -16:00 CET | 8:30am – 10am EST

Downloads available

Contacts

Investor Relations
 investor.relations (at) sanofi.com 
 More contact information

Share